Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of Drugs in Dermatology : JDD|August 16, 2021
Combining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody AloneEmily Hsu, Omar Eton, Akshay V Patel, et al.
Clinical Therapeutics|May 26, 2022
Food as Medicine for Obesity Treatment and ManagementVeronica R Johnson, Tiffani Bell Washington, Shradha Chhabria, et al.
Scientific Reports|January 23, 2025
Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implantScott Thomas, Elysia Roche, Pujan Desai, et al.
Research Square|November 14, 2023
A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo modelsScott Thomas, Elysia Roche, Pujan Desai, et al.
Cancers|January 21, 2023
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 StudyJennifer A Woyach, Paul M Barr, Thomas J Kipps, et al.
Developmental Cell|July 15, 2010
A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditionsMarta M Lipinski, Greg Hoffman, Aylwin Ng, et al.
American Journal of Cancer Research|June 24, 2015
MicroRNA-135b regulates apoptosis and chemoresistance in colorectal cancer by targeting large tumor suppressor kinase 2Yuqi He, Jianxun Wang, Jiheng Wang, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
Persistent Activation of Endothelial Cells is Linked to Thrombosis and Inflammation in Cerebral Cavernous Malformation DiseaseHelios Gallego-Gutierrez, Eduardo Frias-Anaya, Cassandra Bui, et al.
Haematologica|January 13, 2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Leukemia & Lymphoma|January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studiesJan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
Pageof 4